^
Association details:
| Biomarker: | PRKAR1A-MET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer
Published date:
10/13/2022
Excerpt:
In our study, we reported the case of NSCLC harboring a novel PRKAR1A::MET gene fusion dramatic response to crizotinib.
DOI:
https://doi.org/10.1016/j.cllc.2022.10.001
